Guest guest Posted June 29, 2010 Report Posted June 29, 2010 Two new studies point to risks for people taking the diabetes drug Avandia By Rob Stein Washington Post Staff Writer Tuesday, June 29, 2010 Two teams of researchers have produced powerful new evidence that the diabetes drug Avandia increases the risk of heart problems and strokes, renewing questions about the safety of the medication. One analysis, involving more than 35,500 people, found that Avandia significantly raises the chances of a heart attack. The second, a federal analysis of more than 227,500 Medicare patients -- the largest such study to date -- found that the drug boosts the risk for strokes, heart failure and death. The new research, released Monday, should prompt the Food and Drug Administration to remove the drug from the market, according to the researchers who led the analyses and several drug-safety advocates. " There's no reason to keep this drug on the market, " said E. Nissen, a Cleveland Clinic cardiologist who conducted one of the analyses and has long criticized the drug. " This is a harmful drug. " In a statement, GlaxoKline, which makes Avandia, stood by the medication, saying many other, more reliable studies have found no evidence the drug is unsafe. The studies that found no risk were better designed and therefore more reliable, the company says. " Taken together, these trials show that Avandia does not increase the overall risk of heart attack, stroke or death, " the company said in a statement. A Senate investigation released earlier this year concluded that GlaxoKline knew about the possible risks of Avandia for years but failed to sufficiently warn the FDA and consumers. The new data will be considered next month at special joint meeting of two FDA advisory panels to reevaluate Avandia's status, an agency official said. " These are very important papers and will contribute to our evaluation of the safety of this medication, " said M. Sharfstein, the agency's principal deputy commissioner. Avandia had once been one of the world's most popular drugs, with sales exceeding $3 billion annually. The drug was approved in 1999. It treats Type 2 diabetes, the most common form of the disease, by sensitizing the body to insulin, controlling blood sugar levels. It was considered widely effective. But a series of studies have raised questions about whether it raises the risk for cardiovascular problems, a leading cause of death among diabetics. That prompted the FDA to issue a warning about the drug's safety, causing sales to plummet, but the agency decided in 2007 against removing it from the market. Coming on the heels of safety concerns about the blockbuster painkiller Vioxx and other prescription medications, as well as a series of high-profile food safety cases, questions about Avandia have fueled criticism that the FDA is lax in regulating the food and drug industries. ad_icon " I'm hoping with a new administration and new leadership they will act differently, " Nissen said. " This is a defining moment for the new administration. " But J. Graham of the FDA's Center for Drug Evaluation and Research said he doubted the agency would pull the drug. A longtime critic of Avandia and the FDA's drug safety record, he conducted the second new analysis. " FDA, unfortunately, has not changed, " Graham said. " It has not improved its approach to drug safety. It does not value drug safety. " Sharfstein, however, defended the FDA, saying the agency wanted to examine the latest data before making a decision. " FDA is committed to making decisions about Avandia based on all the best available science, " he said. In one of the new analyses, Nissen and a colleague pooled data from 56 studies involving 35,531 people, including 19,509 who took Avandia. In a paper released online by the Archives of Internal Medicine, the researchers concluded that the drug increased the risk for heart attacks from 28 percent to 39 percent. The pair calculated that the drug would cause one heart attack among every 37 to 52 people who used it for five years. In the second analysis, Graham and his colleagues analyzed Medicare records for 227,571 people who took either Avandia or another diabetes drug called Actos from 2006 to 2009. They found that those who took Avandia were 27 percent more likely to have a stroke, 25 percent more likely to develop heart failure and 14 percent more likely to die during the study period than were those who took Actos. Based on the findings, released online by the Journal of the American Medical Association, the researchers estimated that there would be one heart attack, death, stroke or heart failure in every 60 people who took the drug for one year. http://www.washingtonpost.com/wp-dyn/content/article/2010/06/28/AR2010062802089.\ html?wpisrc=nl_cuzhead ========================================================== Public release date: 28-Jun-2010 Contact: Kolonick kolonib@... JAMA and Archives Journals New meta-analysis demonstrates heart risks associated with rosiglitazone Eleven years after the introduction of the diabetes drug rosiglitazone, data from available clinical trials demonstrate an increased risk for heart attack associated with its use and suggest an unfavorable benefit-to-risk ratio, according to a report posted online today that will appear in the July 26 print issue of Archives of Internal Medicine, one of the JAMA/Archives journals. The study was published online in advance of an upcoming Food and Drug Administration meeting that will review the safety of rosiglitazone. Rosiglitazone was approved in 1999 to treat hyperglycemia (high blood glucose levels) among patients with type 2 diabetes, according to background information in the article. Concerns about the cardiovascular safety of rosiglitazone first arose in 2007, when a meta-analysis demonstrated a significantly increased risk for myocardial infarction (heart attack) and a borderline significant increase for cardiovascular death. The debate over the medication's safety has continued during the past three years, and the U.S. Senate Committee on Finance recently released a report providing additional details about internal analyses conducted by the U.S. Food and Drug Administration and by GlaxoKline (GSK), the drug's manufacturer. No large, definitive cardiovascular outcomes trials have been conducted with rosiglitazone. However, as a consequence of a 2004 court settlement in New York, GSK was required to post clinical trial results on a public web site. E. Nissen, M.D., and Kathy Wolski, M.P.H., of The Cleveland Clinic Foundation, searched this GSK data and MEDLINE through February 2010 and identified 56 trials involving 35,531 patients, 19,509 of whom received rosiglitazone and 16,022 who received control medications. In the combined studies, rosiglitazone therapy was associated with a significantly increased risk of myocardial infarction by an estimated 28 percent to 39 percent, although the risk of cardiovascular death was not increased. " An alternative analysis that included trials with no cardiovascular events found a similar hazard, " the authors write. " Subgroups classified by study duration and comparator drug also showed elevated odds ratio estimates. " " These findings are consistent with prior meta-analyses conducted by GSK, the FDA and most independent investigators demonstrating an increased risk of myocardial infarction in patients treated with rosiglitazone, " they continue. " The FDA has announced that it will conduct an advisory committee meeting in July 2010 to consider whether to remove rosiglitazone from the market. " The mechanisms by which rosiglitazone may cause cardiovascular harm are not clear, the authors note, but could involve increases in low-density lipoprotein (LDL, or " bad " cholesterol) levels or genetic effects associated with the production of an enzyme linked to plaque rupture. " The public health implications of these results are considerable. There are more than 23 million persons with diabetes in the United States alone and nearly 300 million worldwide. Cardiovascular disease is the leading cause of death in patients with type 2 diabetes, representing approximately 68 percent of all causes of mortality, " the authors conclude. " Although hyperglycemia has been associated with an increased risk of microvascular adverse events, there are now 12 classes of drugs that are approved to lower blood glucose levels, including insulin. Because no unique benefits of rosiglitazone use have been identified, administration of this agent solely to lower blood glucose levels is difficult to justify. " ### (Arch Intern Med. 2010;170[12]:(doi:10.1001/archinternmed.2010.207). Available pre-embargo to the media at www.jamamedia.org.) Editor's Note: Dr. Nissen has received research support from AstraZeneca, Atherogenics, Eli Lilly, Novartis, Pfizer, Resverlogix, Takeda, Daiichi-Sankyo and Sanofi-Aventis through The Cleveland Clinic Center for Clinical Research in within the last five years. He has consulted for a number of pharmaceutical companies without financial compensation. All honoraria, consulting fees or any other payments from any for-profit entity are paid directly to charity, so he receives neither income nor tax deduction. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc. For more information, contact JAMA/Archives Media Relations at 312/464-JAMA (5262) or e-mail mediarelations@.... http://www.eurekalert.org/pub_releases/2010-06/jaaj-nmd062410.php ============================================== Public release date: 28-Jun-2010 Contact: J. Graham, M.D., M.P.H. david.graham1@... JAMA and Archives Journals Type 2 diabetes medication rosiglitazone associated with increased cardiovascular risks and death A new study published online today by JAMA shows that among patients age 65 years and older, rosiglitazone (a medication for treating Type 2 diabetes) is associated with an increased risk of stroke, heart failure, and all-cause mortality (death) when compared with pioglitazone (another medication for diabetes). The study was published online today in advance of an upcoming Food and Drug Administration meeting that will review the safety of rosiglitazone. The paper will appear in the July 28 print issue of JAMA. " Rosiglitazone and pioglitazone are the only thiazolidinediones (a class of drugs for treating diabetes) currently marketed in the United States, " the authors provide as background information. " Studies have suggested that the use of rosiglitazone may be associated with an increased risk of serious cardiovascular events compared with other treatments for type 2 diabetes. " J. Graham, M.D., M.P.H., from the Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Springs, MD and colleagues, evaluated data from 227,571 Medicare beneficiaries (average age, 74.4 years) who started treatment with rosiglitazone or pioglitazone through a Medicare Part D prescription drug plan from July 2006 through June 2009. The patients were followed for up to three years after the initiation of the medications. " During follow-up, there were 1,746 acute myocardial infarctions [heart attacks] (21.7 percent fatal), 1,052 strokes (7.3 percent fatal), 3,307 hospitalizations for heart failure (2.6 percent fatal), and 2,562 deaths for all causes among cohort members, " the authors report. Analysis showed no differences in the risk for heart attack between rosiglitazone and pioglitazone, but " …our study found that rosiglitazone was associated with a 1.25-fold increase in risk of heart failure compared with pioglitazone, " and " …these data suggest that rosiglitazone was associated with a 1.27-fold increased risk of stroke and a 1.14-fold increased risk of death compared with pioglitazone, " according to the authors. In conclusion, the authors write: " …in a population of more than 227,000 patients 65 years or older who initiated treatment with a thiazolidinedione, we found that, compared with pioglitazone, rosiglitazone was associated with an increased risk of stroke, heart failure, and death and the composite of AMI (heart attack), stroke, heart failure or death. " (JAMA.doi:10.1001/jama.2010.920. Available to the media pre-embargo at www.jamamedia.org.) Editor's Note: This study was funded by the Office of the Assistant Secretary for Planning and Evaluation (ASPE), the Centers for Medicare & Medicaid Services (CMS), and the U.S. Food and Drug Administration (FDA). Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc. Editorial: Rosiglitazone and the Case for Safety Over Certainty In an accompanying editorial, Juurlink, M.D., Ph.D., of the Sunnybrook Research Institute; the Departments of Medicine, Pediatrics and Health Policy, Management, and Evaluation at the University of Toronto; and the Institute for Clinical Evaluative Sciences, Toronto, highlights the importance of the findings of the report by Graham and colleagues in terms of understanding the risks of rosiglitazone. Dr. Juurlink writes, " The epilogue of the rosiglitazone story has yet to be written, but a few observations can now be made with confidence. First, there is no direct evidence that rosiglitazone prevents vascular events in patients with diabetes. Second, converging lines of evidence suggest that rosiglitazone is less safe than pioglitazone, whereas no data suggest that the converse might be true. Third, because the evidence to date is not conclusive, differing views have emerged on how to proceed in the face of uncertainty. … Whether rosiglitazone and pioglitazone really do have different cardiovascular safety profiles is an intriguing question but one with a misplaced focus. Accumulating concerns about rosiglitazone make it difficult to advance a cogent argument why, exactly, a patient might want to receive the drug or why a physician would choose to prescribe it when there is an available and quite possibly safer alternative. " (JAMA.doi:10.1001/jama.2010.954. Available to the media pre-embargo at www.jamamedia.org) Editor's Note: Please see the article for additional information author affiliations, financial disclosures, funding and support, etc. ### For more information, contact JAMA/Archives Media Relations at 312/464-JAMA (5262) or e-mail mediarelations@.... To contact editorial author Juurlink, M.D., Ph.D., call Deborah Creatura at or e-mail: deborah.creatura@.... http://www.eurekalert.org/pub_releases/2010-06/jaaj-t2d062410.php Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.